Form 4: BIOLIFE SOLUTIONS Director Sells Shares Under 10b5-1 Plan

BIOLIFE SOLUTIONS Director Amy DuRoss reported a pre-scheduled sale of 2,000 common stock shares at $24.6 each.

Summary

• Amy DuRoss, a Director at BIOLIFE SOLUTIONS INC (BLFS), reported a transaction involving the sale of common stock.
• The transaction, dated December 15, 2025, was made pursuant to a Rule 10b5-1(c) plan.
• A total of 2,000 shares of common stock were disposed of at a price of $24.6 per share.
• Following this transaction, Amy DuRoss beneficially owns 18,687 shares of BIOLIFE SOLUTIONS INC common stock.

Sentiment

Score: 6

Explanation: The transaction was executed pursuant to a Rule 10b5-1 plan, indicating a pre-scheduled sale not based on current material non-public information. This mitigates the typical negative sentiment associated with insider selling, making the transaction largely neutral in terms of market signal.

Industry Context

This filing reports a routine insider transaction by a director, which is a common occurrence in publicly traded companies and typically reflects personal financial planning rather than a direct commentary on industry trends or company performance.

Related Party Transactions

• Amy DuRoss, a Director of BIOLIFE SOLUTIONS INC, sold 2,000 shares of common stock at $24.6 per share pursuant to a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders: The sale is a pre-scheduled transaction under a 10b5-1 plan, which generally minimizes any perceived negative signal from insider selling, thus having a neutral to minimal impact on shareholder sentiment.

Key Dates

Keywords

BIOLIFE SOLUTIONS, BLFS, Amy DuRoss, Insider Trading, Form 4, Stock Sale, Director Transaction, 10b5-1 Plan